ITGB3 (CD61/Integrin beta 3) Drug Discovery Landscape & Assay Solutions
- By admin
- 22 Aug 2026
- Comments
Market Intelligence, Clinical Progress, and High-Purity Reagents for Thrombosis and Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ITGB3 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (ECD-Fc) | Human/Mouse/Cyno ITGB3 ECD-Fc. High purity (>95%), Endotoxin <1EU/µg. Sequence Verified. HEK293 Expressed (Native Glycosylation). | View ITGB3 Products |
| Heterodimer Partner – ITGA2B (CD41) | Recombinant protein for functional GPIIb/IIIa complex formation. Theoretical MW verified. | View ITGA2B Products |
| Heterodimer Partner – ITGAV (CD51) | Protein or lentivirus for alphavbeta3 vitronectin receptor studies in oncology. | View ITGAV Products |
| Gene Delivery | ITGB3 Lentivirus Premade Particles. Full-length ORF for stable cell line construction. Preserves conformational integrity. | View ITGB3 Products |
| Benchmark Ab | Anti-ITGB3 (Abciximab biosimilar). Chimeric Fab fragment positive control. Sequence Verified. | View ITGB3 Products |
| Validator | ITGB3 siRNA Set for knockdown verification and specificity controls. | View ITGB3 Products |
| Related Target A | CD51 (ITGAV) – Forms alphaVbeta3 heterodimer (angiogenesis/oncology focus). | View CD51 Products |
| Related Target B | CD41 (ITGA2B) – Forms alphaIIbbeta3 heterodimer (thrombosis focus). | View CD41 Products |
Technical Specifications for Critical Assays
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Heterodimer Integrity (ITGB3+ITGA2B/ITGAV) | Co-expression compatible Lentivirus vectors. Sequence Verified full-length ORFs maintaining native transmembrane domains. |
| Conformational State Discrimination (Bent vs Extended) | High Purity (>95%) ECD proteins enabling SPR/BLI ligand-binding kinetics. Theoretical MW confirmed by mass spec. |
| Cross-species Cyno/Mouse Evaluation | Human/Mouse/Cyno ortholog proteins available with matching HEK293 glycosylation patterns for translational studies. |
| Beta-Integrin Selectivity (Off-target Screening) | Homolog panel proteins (ITGB1, ITGB5, ITGB6) strictly verified by mass spec for counter-screening. |
| Functional Validation | Clinical Benchmark Antibodies (Abciximab format) included as positive controls. |
Live ITGB3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Molecular Domains & Key Mutations
ITGB3 (Integrin beta-3) is a transmembrane glycoprotein with key extracellular domains essential for ligand binding and heterodimer formation:
- PSI domain – cysteine-rich region involved in integrin activation (UniProt P05106).
- VWFA domain – von Willebrand factor type A domain, contains the MIDAS motif for cation-dependent ligand binding.
- I-EGF 1 domain – first integrin EGF-like domain, stabilizes the bent conformation.
Clinically significant mutations (from UniProt P05106):
- rs544276300 (Kha(b) alloantigen) – probable risk factor for FMAIT1 (fetomaternal alloimmune thrombocytopenia).
- rs5918 (Pl(A2) alloantigen) – risk factor for FMAIT1; associated with platelet alloantigen expression.
- Unnamed mutation (VAR_069920) – in Glanzmann thrombasthenia (GT2), unknown significance; severe type 1 phenotype; prevents normal expression.
Global Clinical Landscape & Future Outlook
The therapeutic landscape for ITGB3 (Integrin beta 3/CD61) is undergoing strategic recalibration. Historically, first-generation GPIIb/IIIa antagonists (Abciximab, Tirofiban, Eptifibatide) revolutionized acute coronary syndrome management, but bleeding liabilities constrained long-term use, leading to reduced investment in antithrombotic small molecules. The current R&D pivot focuses on oncology applications targeting the alphavbeta3 (ITGAV/ITGB3) vitronectin receptor to inhibit tumor angiogenesis and metastatic dissemination. Next-generation modalities include conformation-state specific inhibitors, tissue-restricted delivery systems, and targeted radionuclide conjugates (RDCs) or antibody-drug conjugates (ADCs) that leverage integrin overexpression on tumor vasculature to bypass hematologic toxicity.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Antagonist | Legacy Pharma (Merck, J&J), Medicure | Acute Thrombosis, Angina | Conformational binding assays (need high-purity heterodimeric ECD) |
| Recombinant Fab (Biosimilar) | Centocor (Reference) | PCI, Anticoagulation | Heterodimer competition assays (need ITGA2B/ITGB3 complex) |
| Integrin-Targeted ADC | Emerging Biotechs | Solid Tumors, Glioblastoma | Internalization & trafficking assays (need stable cell lines via Lentivirus) |
| Radionuclide Conjugates (RDC) | Specialty Radiopharma | Prostate Cancer, Metastatic | High-affinity binding (strictly sequence-verified antigens) |
| Antagonist mAb (Oncology) | Cilengitide analogs | Glioma, Melanoma | Selectivity vs alphavbeta5 (need ITGAV/ITGB5 panels) |